The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors.

The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors.

Biopharma deal value through the first five months of 2026 reached $135.36 billion, outpacing every prior year and topping 2025’s previous high of $103.92 billion. May was the year’s biggest month so far at $41.78 billion in transactions, making it one of the strongest individual months on record, and far outpacing April’s $13.87 billion.

Biopharma deal value through the first five months of 2026 reached $135.36 billion, outpacing every prior year and topping 2025’s previous high of $103.92 billion. May was the year’s biggest month so far at $41.78 billion in transactions, making it one of the strongest individual months on record, and far outpacing April’s $13.87 billion. May 2026 comes in third in recent years in terms of deal value, after October 2023’s $44.91 billion and December 2022’s $42.45 billion.

Innovent Biologics Inc. and Pfizer Inc. have entered into a strategic global licensing and collaboration agreement for the research and development of 12 new breakthrough early-stage and de novo cancer medicines.

Biopharma deal value reached $79.22 billion in the first quarter (Q1) 2026, marking a strong start to the year and an increase of about 17% from $67.6 billion in Q1 2025 and similar to $78.93 billion in Q4 2025. The total is the highest first-quarter tally in recent years, and the highest quarter since Q4 2025 brought $80.65 billion.

BioWorld tracked 209 clinical trial readouts across phases I through III in March 2026, up from 152 in February and 144 in January. Among late-stage programs, 26 phase III trials reported positive results, two produced mixed results, and three failed to meet key endpoints. By phase, March updates included 62 from phase I, 74 from phase II and 73 phase III.

BioWorld tracked 209 clinical trial readouts across phases I through III in March 2026, up from 152 in February and 144 in January. Among late-stage programs, 26 phase III trials reported positive results, two produced mixed results, and three failed to meet key endpoints. By phase, March updates included 62 from phase I, 74 from phase II and 73 phase III.

Biopharma deal value reached $79.22 billion in the first quarter (Q1) 2026, marking a strong start to the year and an increase of about 17% from $67.6 billion in Q1 2025 and similar to $78.93 billion in Q4 2025. The total is the highest first-quarter tally in recent years, and the highest quarter since Q4 2025 brought $80.65 billion.

Innovent Biologics Inc. has presented preclinical data on IBI-3055, a trispecific T-cell engager for the treatment of autoimmune diseases. This trispecific antibody targets CD19, BCMA and CD3, and features an innovative 1+1+1 T-cell engager design with CD3 masking to minimize non-specific T-cell activation.